Articles tagged "Hepatocellular carcinoma"

2019 American Transplant Congress
Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
D. Salerno¹, N. Lange¹, E. Simoneau², C. Sammons³, D. Bley¹, R. S. Brown Jr⁴, J. Emond², K. Halazun⁵
¹Pharmacy, NewYork-Presbyterian Hospital, New York, NY, ²Surgery, Columbia University Irving Medical Center, New York, NY, ³Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Medicine, Weill Cornell Medicine, New York, NY, ⁵Surgery, Weill Cornell Medicine, New York, NY
*Purpose: The optimal immunosuppression for liver transplant recipients (LTR) with hepatocellular carcinoma (HCC) is unknown. Basiliximab, an interleukin-2 receptor antagonist (IL-2RA), confers immunosuppression for LTR…
2019 American Transplant Congress
Long Term Outcomes of Patients Transplanted for Hepatocellular Carcinoma with Human Immunodeficiency Virus Infection
R. Gedaly-Eidelman, E. Chacon, P. Eman, M. Gupta, J. Berger, A. El-Husseini, X. Mei, F. Marti, L. Turcios, M. Shah
University of Kentucky, Lexington, KY
*Purpose: Several studies have reported that HIV+ patients are 4-6 times more likely to develop HCC than uninfected individuals. Our aim was to assess outcomes…
2019 American Transplant Congress
Outcomes of Liver Transplantation for Hepatocellular Carcinoma in Septuagenarians
M. Najjar¹, K. Bruestle¹, P. Jiang¹, E. Lieberman¹, R. Hwang¹, A. Mathur¹, E. C. Verna¹, A. Griesemer¹, B. Samstein², T. Kato¹, Y. M. Saenger¹, K. J. Halazun², J. C. Emond¹
¹Columbia University Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: The impact of advanced age on liver transplantation (LT) for hepatocellular carcinoma (HCC) has not been well studied. We sought to compare post-OLT survival…
2019 American Transplant Congress
Policy Changes in Liver Graft Allocation for Hepatocellular Carcinoma in the USA: Improved Survival for African American Recipients
M. Molinari¹, D. Jorgensen¹, A. Tevar¹, C. Hughes¹, A. Humar¹, N. Jonassaint²
¹Surgery, University of Pittsburgh Medical Centre, Pittsburgh, PA, ²Medicine, University of Pittsburgh Medical Centre, Pittsburgh, PA
*Purpose: To evaluate the effect of policy changes in liver graft allocation for hepatocellular carcinoma (HCC) on the overall survival of patients of different ethnicities…
2019 American Transplant Congress
Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma
M. Nazzal¹, R. Steele², R. Ray³, N. Phillips², J. Long⁴, R. Ray²
¹Surgery, Saint Louis University, Saint Louis, MO, ²Pathology, Saint Louis University, Saint Louis, MO, ³Internal Medicine, Saint Louis University, Saint Louis, MO, ⁴Comparative Medicine, Saint Louis University, Saint Louis, MO
*Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…
2019 American Transplant Congress
Long Term Impact of Intraoperative Autologous Blood Transfusion on HCC Recurrence in Liver Transplantation
G. Kelly¹, J. L. Pasko¹, E. Dewey², E. Maynard¹, S. L. Orloff¹, C. Enestvedt¹
¹Division of Abdominal Transplant, OHSU, Portland, OR, ²Department of General Surgery, OHSU, Portland, OR
*Purpose: The aim of this study was to determine whether intraoperative autologous transfusion in liver transplant patients with HCC affects the rate of recurrence.*Methods: We…
2019 American Transplant Congress
DOME: A New Strategy for Prioritizing Hepatocellular Carcinoma Patients on the Liver Transplant Waitlist
C. Rickert¹, M. Akan², Z. Leung³, J. F. Markmann¹, S. Tayur², H. Zhao³, H. Yeh¹
¹Massachusetts General Hospital, Boston, MA, ²Tepper School of Business, Carnegie Mellon University, Pittsburgh, PA, ³City University of Hong Kong, Hong Kong, China
*Purpose: Currently, adult HCC patients are prioritized for liver transplantation by receiving MELD exception points, determined primarily by time on waitlist without regard to actual…
2019 American Transplant Congress
Outcome Of Living Donor Liver Transplantation In Elderly Patients >65 Years With And Without Hepatocellular Carcinomas: A Retroepsective Analysis
A. Thorat, L. Jeng, S. Hsu, H. Yang, C. Yeh, T. Chen, K. Poon, P. Li
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: The elderly patients > 65 years with end-stage liver disease that require liver transplantation has been steadily increased over last decade in Taiwan and…
2019 American Transplant Congress
Adjuvant Immunotherapeutic Approach For Liver Transplant Recipients With Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
M. Ohira¹, R. Hotta¹, Y. Imaoka¹, K. Sato¹, Y. Tanaka¹, A. G. Tzakis², S. Nishida³, H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²Cleveland Clinic Florida, Weston, FL, ³New York Medical College, Valhalla, NY
*Purpose: Although liver transplantation (LT) is a preferred treatment for selected patients with Hepatocellular carcinoma (HCC), HCC-recurrence would be a still important medical problem. Most…
2019 American Transplant Congress
Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation
D. Kim, J. Lee, S. Kim, K. In, D. Joo, S. Kim, M. Kim
Severance hospital, Seoul, Korea, Republic of
*Purpose: There was no distinct guideline how to take into account the effect of pretransplant locoregional treatment (LRT) in hepatocellular carcinoma (HCC) staging system. The…

« Previous Page
1
…
8
9
10
11
12
…
23
Next Page »